German aesthetic products firm Merz Pharma has commercially launched its Cellfina System in select European countries for the treatment of cellulite.
Intended for long-term cellulite reduction, the Cellfina System is designed for the precise release of targeted structural tissue (fibrous septae).
The system has been developed as a minimally invasive procedure to treat the underlying structural cause of cellulite, with both CE-Mark and clearance from the US Food and Drug Administration (FDA).
The device is claimed to produce results that last for a minimum of three years.
Merz Pharma EMEA vice-president and regional head Stefan Brinkmann said: “Cellulite treatment is an aesthetic category where the market need has remained largely unmet and where patients have often been dissatisfied with available options.
“With the introduction of the Cellfina System to the European market, Merz is now able to provide physicians with a technology that delivers an effective and long-term solution to the problem of cellulite dimples.”
The system employs an advanced technology in combination with a process called subcision and requires a single in-office procedure.
Merz evaluated the system in a clinical study with 55 US patients who underwent treatment.
The results showed that the device improved cellulite appearance in 97% of patients for three years and 93% experienced satisfaction with their treatment.
After three years, the global aesthetic improvement scale (GAIS) reported that 100% of patients experienced a noticeable improvement, with common side effects being soreness, tenderness and bruising that resolved with time.